The investment bank, which maintained its $60 price target for the company's stock, said it is looking for signs of revenue acceleration.
The investment bank initiated coverage on Rosetta Genomics and Veracyte, rating the molecular diagnostic firms' shares speculative buy and buy, respectively.
The company also said that its cash burn rate for Q2 is estimated to be about $4.8 million, or $1.3 million more than its average cash burn.
Cantor will offer PacBio's stock in an "at-the-market" offering, though the investment bank may also sell the shares through other methods.
Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.
Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.
China is embracing preimplantation genetic diagnosis, Nature News reports.
In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.